Less scars with new product

A new Swedish product for post surgical scar formation enters clinical development.

Coordination of world-class research facilities

Four unique world-class research facilities are located just a few hours apart. Properly utilised, a Nordic centre for world-leading life science innovation and...

Framåt för Neurovive i fas II

Fas II-studien Chic går in i nästa fas när läkemedelskandidaten Neurostat mot traumatiska hjärnskador passerar säkerhetsutvärdering.

Before you choose a CRO

– We are a small company and it is very important for us to maintain our core competence within development of novel nanomaterials, Tove Sivik Sonne, Head of De...

Lucka 17 - Titta vem som finns här

Det lackar mot jul och det vill vi uppmärksamma tillsammans med er. Varje dag fram till jul får vi här veta vad profiler i life science-världen har på sin önskelista.

Engage with your CMO early

Gordon Hutton is Materials Science Lead at Thermo Fisher Scientific’s, formerly GSK, small molecule API site in Cork, Ireland.

Swiss allergy therapy convinces

Cytos Biotechnology presents promising results in a study of a new therapy against allergy and asthma.

Brexit looking back and looking forward

More than 3 years have passed after the vote and there is still uncertainty around the outcome although the UK December 12 election set a clearer course towards...

Krönika: Collaboration across borders

Swedish and Danish Life Science – are there still untapped synergies?

With the increasing developments in life sciences over the past decade and strong support for the sector’s strategic importance from both the Sweden and Danish ...

Happy exhibitors!

There were fewer vistors this year but most exhibitors are content.

They’re all doing it – buying drug research

It is not easy to navigate the complex infrastructure for drug development in Sweden, where various contract players exist alongside the pharmaceutical companies.

New diagnostic test soon ready for the market

Meet the governmental life science office

More clinical trials, promotion for digitisation and interoperability together with increased use of data generated by both healthcare and individuals. The duti...

Samuel Lagercrantz: Collaboration and joint efforts are the key to success

Although many questions about Covid-19 remain unanswered, the development of drugs and vaccines has been incredibly rapid, writes Samuel Lagercrantz, Life Scien...

An industry emerging from crisis

"Scanlab is normally indicative of the status of investment incentives in the laboratory industry "

International models among science parks

Science parks have become a part of modern communities. With science parks in Oxford, Cambridge and Nice setting good examples, a special potential emerged. Cou...

How to become globally competitive

Here Gunilla Osswald from BioArctic share her experience of scaling up and be competative on the global arena.

Future drugs from Amaryllis

A Danish research team has discovered possibolities to extract drugs fro Amaryllis.

Nya resultat om immunförsvarets reaktion vid svår covid-19

Forskare har identifierat flera celltyper som är centrala vid immunförsvarets reaktion vid covid-19.

They’re all doing it – buying drug research

December 12 the time has come for this year's annual partnering meeting Pharma Outsourcing in Stockholm. In Sweden this is a growing business, with Recipharm as...

MVA:s CEO: “Our investments should improve people´s everyday lives”

Involuntary infertility and diabetes are two of the areas on the agenda of the Medicon Valley Alliance.

SciLifeLab-pris till fyra unga forskare

Stanfordforskaren Neir Eshel tilldelas förstapriset när Science & SciLifeLab Prize for Young Scientists delas ut.

Samuel Lagercrantz: Framgången kommer efter många misslyckanden

De allra flesta av de idéer och strategier mot covid-19 som man nu jobbar med kommer att gå i stöpet, men det kan räcka med att en enda fungerar, skriver Samuel Lagercrantz.